July 19, 2018 / 12:19 PM / 4 months ago

Mersana's cancer drug trial put on hold by FDA; shares halted

(Reuters) - Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient’s death was possibly linked to the treatment.

No new patients will be enrolled in the study, but the current participants will continue to receive the drug, XMT-1522, Mersana said.

The experimental treatment is being tested in patients whose advanced tumors express a protein called HER2, including those with cancers of the breast, lung and stomach.

The partial clinical hold does not affect early stage trials of Mersana’s other cancer drug, XMT-1536, which are currently underway, the company said.

Mersana’s shares were halted in premarket trade.

Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur and Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below